Immunic
IMUX
57 hedge funds and large institutions have $65.6M invested in Immunic in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 6 closing their positions.
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
36% more funds holding
Funds holding: 42 → 57 (+15)
27% more capital invested
Capital invested by funds: $51.7M → $65.6M (+$13.9M)
0% more ownership
Funds ownership: 0.06% → 0.07% (+0%)
97% less call options, than puts
Call options by funds: $14K | Put options by funds: $454K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.16M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.09M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$1.78M |
| 4 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$1.32M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.51M |
| 2 |
Millennium Management
New York
|
-$955K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$478K |
| 4 |
DY
Dowling & Yahnke
San Diego,
California
|
-$252K |
| 5 |
ECM
Element Capital Management
New York
|
-$179K |
IMUX Hedge Fund Activity: Q4 2017 in Review
57 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2017, worth a combined $65.6M — up 27% from $51.7M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IMUX positions and 6 closed out — a net gain of 15 holders — while 17 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $3.16M. The largest seller was Fidelity Investments, cutting an estimated $5.51M.
- 57 institutional investors held Immunic (IMUX) as of Q4 2017, up from 42 in Q3 2017.
- Funds reported $65.6M of Immunic stock for Q4 2017, up 27% quarter-over-quarter.
- 21 funds opened new Immunic positions in Q4 2017 and 6 closed out, a net change of +15 holders.
- The largest Immunic buyer in Q4 2017 was BlackRock, an estimated $3.16M added.
- The largest Immunic seller in Q4 2017 was Fidelity Investments, an estimated $5.51M sold.
Based on aggregated 13F filings for Q4 2017.